Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (16760)
All Articles published online
|
Publishing Process of This Article
|
Nov 6, 2015 (publication date) through May 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ye B, van Langenberg DR. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J Gastrointest Pharmacol Ther 2015; 6(4): 137-144 [PMID: 26558148 DOI: 10.4292/wjgpt.v6.i4.137] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v6/i4/137.htm |
| Number | Citing Articles |
| 1 |
Shomron Ben-Horin, Nir Salomon, Georgios Karampekos, Nikos Viazis, Adi Lahat, Bella Ungar, Rami Eliakim, Rafael Kuperstein, Ofra Kriger-Sharabi, Hilla Reiss-Mintz, Henit Yanai, Iris Dotan, Eran Zittan, Nitsan Maharshak, Ayal Hirsch, Michal Weitman, Gerassimos J. Mantzaris, Uri Kopylov. Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology 2024; 22(2): 347 doi: 10.1016/j.cgh.2023.05.023
|
| 2 |
Femke Crouwel, Hans J C Buiter, Nanne K de Boer. Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2021; 15(2): 307 doi: 10.1093/ecco-jcc/jjaa143
|
| 3 |
Andrei Tudor Cernomaz, Gabriela Bordeianu, Cristina Terinte, Cristina Maria Gavrilescu. Nonasthmatic eosinophilic bronchitis in an ulcerative colitis patient – a putative adverse reaction to mesalazine: A case report and review of literature. World Journal of Clinical Cases 2020; 8(18): 4162-4168 doi: 10.12998/wjcc.v8.i18.4162
|
| 4 |
Belinda Jackson, Peter De Cruz. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2018; 12(11): 1079 doi: 10.1080/17474124.2018.1530109
|
| 5 |
Aurelio Romero-Castro, Mara Gutiérrez-Sánchez, José Correa-Basurto, Martha Cecilia Rosales Hernández, Itzia Irene Padilla Martínez, Jessica Elena Mendieta-Wejebe, Mária A. Deli. Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity. PLOS ONE 2016; 11(7): e0159889 doi: 10.1371/journal.pone.0159889
|
| 6 |
You Sun Kim. How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?. The Korean Journal of Gastroenterology 2018; 71(2): 74 doi: 10.4166/kjg.2018.71.2.74
|
| 7 |
Eriko Yasutomi, Sakiko Hiraoka, Shumpei Yamamoto, Shohei Oka, Mami Hirai, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Jun Kato, Hiroyuki Okada. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. Journal of Clinical Medicine 2019; 8(12): 2109 doi: 10.3390/jcm8122109
|
| 8 |
Ayesha Akbar, Ian Arnott, Nicholas A Kennedy, Jonathan Nolan, Simon Peake, Simon R Whiteoak, Chris Probert, Aileen Fraser, Alex Cheshire, Allyson Lewis, Kathleen Sugrue, Susan Laird, Glyn Scott. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. British Journal of Hospital Medicine 2021; 82(10): 1 doi: 10.12968/hmed.2021.0399
|
| 9 |
Nazlı Seray Bostancı, Senem Büyüksungur, Nesrin Hasirci, Ayşen Tezcaner. Potential of pectin for biomedical applications: a comprehensive review. Journal of Biomaterials Science, Polymer Edition 2022; 33(14): 1866 doi: 10.1080/09205063.2022.2088525
|
| 10 |
You Sun Kim. Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators. Journal of the Korean Medical Association 2021; 64(9): 596 doi: 10.5124/jkma.2021.64.9.596
|
| 11 |
Alberto Gomes Tavares Junior, Jennifer Thayanne Cavalcante de Araújo, Jonatas Lobato Duarte, Amanda Letícia Polli Silvestre, Leonardo Delello Di Filippo, Marlus Chorilli. Polymeric Systems for Colon-specific Mesalazine Delivery in the
Intestinal Bowel Diseases Management. Current Medicinal Chemistry 2023; 30(12): 1351 doi: 10.2174/0929867329666220707102912
|
| 12 |
W. Li, Z.‐M. Zhang, X.‐L. Jiang. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta‐analysis. Colorectal Disease 2016; 18(7) doi: 10.1111/codi.13393
|
| 13 |
Hafiza Ammara Naseem, Tariq Aziz, Habib-ur-Rehman Shah, Khalil Ahmad, Sajidah Parveen, Muhammad Ashfaq. Rational synthesis and characterization of medicinal phenyl diazenyl-3-hydroxy-1h-inden-1-one azo derivatives and their metal complexes. Journal of Molecular Structure 2021; 1227: 129574 doi: 10.1016/j.molstruc.2020.129574
|
| 14 |
Denise D. Young, Sharon Perry, Sindhoosha Malay, Thomas J. Sferra, Michael Finkler, Jonathan Moses. Natural History of Pediatric Patients With Crohn’s Disease Treated With Mesalamine Therapy. JPGN Reports 2023; 4(4): e379 doi: 10.1097/PG9.0000000000000379
|
| 15 |
Riadh Jazrawi. Can more be done to optimise the effect of mesalazine for IBD patients with mild to moderate ulcerative colitis?. Gastrointestinal Nursing 2024; 22(Sup3): S1 doi: 10.12968/gasn.2024.22.Sup3.S1
|
| 16 |
Hossein Shahdadi Sardo, Farinaz Saremnejad, Sara Bagheri, Abbas Akhgari, Hadi Afrasiabi Garekani, Fatemeh Sadeghi. A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. International Journal of Pharmaceutics 2019; 558: 367 doi: 10.1016/j.ijpharm.2019.01.022
|
| 17 |
Aline Martins dos Santos, Suzana Gonçalves Carvalho, Andréia Bagliotti Meneguin, Rafael Miguel Sábio, Maria Palmira Daflon Gremião, Marlus Chorilli. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives. Journal of Controlled Release 2021; 334: 353 doi: 10.1016/j.jconrel.2021.04.026
|
| 18 |
Riadh Jazrawi. Can more be done to optimise the effect of mesalazine for IBD patients with mild to moderate ulcerative colitis?. Gastrointestinal Nursing 2024; 22(Sup3a): S1 doi: 10.12968/gasn.2024.22.Sup3a.S1
|
| 19 |
Imtiyaz Ahmed Najar, Archana Sharma, Abdulrahman Alshammari, Thamer H. Albekairi, Metab Alharbi, Taief Ahmad Dar, Zulfkar Latief Qadrie, Atul Kabra, A.M.J Newton, Manish Kumar. Anti-oxidant and anti-inflammatory potential of different polymer-based mesalamine delayed-release granules in TNBS-induced ulcerative colitis in wistar rats. Saudi Pharmaceutical Journal 2024; 32(1): 101910 doi: 10.1016/j.jsps.2023.101910
|
| 20 |
Michael Schütt, Konstantinos Stamatopoulos, Hannah K. Batchelor, Mark J. H. Simmons, Alessio Alexiadis. Modelling and Simulation of the Drug Release from a Solid Dosage Form in the Human Ascending Colon: The Influence of Different Motility Patterns and Fluid Viscosities. Pharmaceutics 2021; 13(6): 859 doi: 10.3390/pharmaceutics13060859
|
| 21 |
Jan Goelen, Benoni Alexander, Haren Eranga Wijesinghe, Emily Evans, Gopal Pawar, Richard D. Horniblow, Hannah K. Batchelor. Quantification of Fluid Volume and Distribution in the Paediatric Colon via Magnetic Resonance Imaging. Pharmaceutics 2021; 13(10): 1729 doi: 10.3390/pharmaceutics13101729
|
| 22 |
Charlie Andrews. Ulcerative colitis. InnovAiT: Education and inspiration for general practice 2019; 12(9): 501 doi: 10.1177/1755738019856030
|
| 23 |
Amandeep Singh, Kirandeep Kaur, Uttam Kumar Mandal, Raj Kumar Narang. Nanoparticles as Budding Trends in Colon Drug Delivery for the Management of Ulcerative Colitis. Current Nanomedicine 2020; 10(3): 225 doi: 10.2174/2468187310999200621200615
|
| 24 |
Angela Effinger, Caitriona M O'Driscoll, Mark McAllister, Nikoletta Fotaki. Impact of gastrointestinal disease states on oral drug absorption – implications for formulation design – a PEARRL review. Journal of Pharmacy and Pharmacology 2019; 71(4): 674 doi: 10.1111/jphp.12928
|
| 25 |
Camilla Virili, Ilaria Stramazzo, Maria Giulia Santaguida, Giovanni Bruno, Nunzia Brusca, Silvia Capriello, Miriam Cellini, Carola Severi, Lucilla Gargano, Marco Centanni. Ulcerative Colitis as a Novel Cause of Increased Need for Levothyroxine. Frontiers in Endocrinology 2019; 10 doi: 10.3389/fendo.2019.00233
|
| 26 |
Vajk Farkas, Gábor Turczel, János Deme, Attila Domján, László Trif, Anvar Mirzaei, Dang Vu Hai, Márton Nagyházi, Sándor Kéki, Péter Huszthy, Róbert Tuba. Synthesis and characterization of a pH-responsive mesalazine-polynorbornene supramolecular assembly. Polymer Chemistry 2021; 12(14): 2175 doi: 10.1039/D1PY00194A
|
| 27 |
Zonghui Ma, Andrew A. Bolinger, Jia Zhou, Bing Tian. Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics. Expert Opinion on Therapeutic Targets 2023; 27(1): 1 doi: 10.1080/14728222.2023.2175317
|
| 28 |
Andréia Bagliotti Meneguin, Rafael Miguel Sábio, Maurício Palmeira Chaves de Souza, Richard Perosa Fernandes, Anselmo Gomes de Oliveira, Marlus Chorilli. Cellulose Nanofibers Improve the Performance of Retrograded Starch/Pectin Microparticles for Colon-Specific Delivery of 5-ASA. Pharmaceutics 2021; 13(9): 1515 doi: 10.3390/pharmaceutics13091515
|
| 29 |
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh. Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intestinal Research 2020; 18(4): 355 doi: 10.5217/ir.2019.09176
|
| 30 |
Mohammad Mukim, Mohit Chaturvedi, Rakesh Patel, Supriya Roy, Pratishtha Sharma, Varunesh Chaturvedi, Saloni Goyal, Mohsina F. Patewkar. CROHN’S DISEASE: A REVIEW ON EPIDEMIOLOGY, DIAGNOSIS AND THERAPEUTIC MANAGEMENT. Indian Drugs 2022; 59(09): 16 doi: 10.53879/id.59.09.12577
|
| 31 |
Kristine Paridaens, John R. Fullarton, Simon P. L. Travis. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Current Medical Research and Opinion 2021; 37(11): 1891 doi: 10.1080/03007995.2021.1968813
|
| 32 |
Jacqueline N. Chu, Giovanni Traverso. Foundations of gastrointestinal-based drug delivery and future developments. Nature Reviews Gastroenterology & Hepatology 2022; 19(4): 219 doi: 10.1038/s41575-021-00539-w
|
| 33 |
Hisako Ibaraki, Naruhiro Hatakeyama, Naoki Arima, Akihiro Takeda, Yasuo Seta, Takanori Kanazawa. Systemic delivery of siRNA to the colon using peptide modified PEG-PCL polymer micelles for the treatment of ulcerative colitis. European Journal of Pharmaceutics and Biopharmaceutics 2022; 170: 170 doi: 10.1016/j.ejpb.2021.12.009
|
| 34 |
Michal Gorzkiewicz, Monika Marcinkowska, Maciej Studzian, Iwona Karwaciak, Lukasz Pulaski, Barbara Klajnert-Maculewicz. Mesalazine–PAMAM Nanoparticles for Transporter-Independent Intracellular Drug Delivery: Cellular Uptake and Anti-Inflammatory Activity. International Journal of Nanomedicine 2023; : 2109 doi: 10.2147/IJN.S390763
|
| 35 |
Nikola Smatlik, Nourhan Mortada, Martin Röcken, Amir S. Yazdi, Manfred Zierhut. Mesalazine Suppresses Proinflammatory Cytokines in Patients with Acute Anterior Uveitis Independently of HLA-B27. Ocular Immunology and Inflammation 2022; 30(6): 1369 doi: 10.1080/09273948.2021.1873396
|
| 36 |
Yi Li, Jianping Chen, Andrew A Bolinger, Haiying Chen, Zhiqing Liu, Yingzi Cong, Allan R Brasier, Irina V Pinchuk, Bing Tian, Jia Zhou. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 2021; 27(Supplement_2): S38 doi: 10.1093/ibd/izab190
|
| 37 |
Mirza Bojić, Željko Debeljak, F. Peter Guengerich. Pharmacogenomics in Clinical Practice. 2023; : 13 doi: 10.1007/978-3-031-45903-0_2
|
| 38 |
Siddharth Singh, Joseph D. Feuerstein, David G. Binion, William J. Tremaine. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019; 156(3): 769 doi: 10.1053/j.gastro.2018.12.008
|
| 39 |
Stephan R. Künzel, Luise Winter, Maximilian Hoffmann, Theresa A. Kant, Jessica Thiel, Romy Kronstein‐Wiedemann, Erik Klapproth, Kristina Lorenz, Ali El‐Armouche, Susanne Kämmerer. Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice. Physiological Reports 2023; 11(17) doi: 10.14814/phy2.15809
|
| 40 |
Ayesha Akbar, Ian Arnott, Nicholas A Kennedy, Jonathan Nolan, Simon Peake, Simon R Whiteoak, Chris Probert, Aileen Fraser, Alex Cheshire, Allyson Lewis, Kathleen Sugrue, Susan Laird, Glyn Scott. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Gastrointestinal Nursing 2022; 20(1): 34 doi: 10.12968/gasn.2022.20.1.34
|
| 41 |
Vanda Sargautiene, Renāte Ligere, Ineta Kalniņa, Ida Jākobsone, Vizma Nikolajeva, Aleksejs Derovs. The Effect of 5-Aminosalicylic Acid on Intestinal Microbiota. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2020; 74(2): 53 doi: 10.2478/prolas-2020-0008
|
| 42 |
Manja Newe, Theresa A. Kant, Maximilian Hoffmann, Johanna S. E. Rausch, Luise Winter, Karolina Künzel, Erik Klapproth, Claudia Günther, Stephan R. Künzel. Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice. Naunyn-Schmiedeberg's Archives of Pharmacology 2021; 394(11): 2233 doi: 10.1007/s00210-021-02135-w
|
| 43 |
El Bethel Lalthavel Hmar, Sujata Paul, Nayanmoni Boruah, Priyanka Sarkar, Sudarshana Borah, Hemanta Kumar Sharma. Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role?. Current Pathobiology Reports 2021; 9(1): 9 doi: 10.1007/s40139-020-00218-6
|
| 44 |
Yongjia Hu, Xueli Jin, Fei Gao, Ting Lin, Hui Zhu, Xiao Hou, Yu Yin, Shidong Kan, Daijie Chen. Selenium-enriched Bifidobacterium longum DD98 effectively ameliorates dextran sulfate sodium-induced ulcerative colitis in mice. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.955112
|
| 45 |
Keyu Ren, Chunming Yong, Yanting Wang, Hongyun Wei, Kun Zhao, Baoguo He, Mingjuan Cui, Yunqing Chen, Jin Wang. Cytomegalovirus Pneumonia in Inflammatory Bowel Disease: Literature Review and Clinical Recommendations. Infection and Drug Resistance 2023; : 6195 doi: 10.2147/IDR.S420244
|
| 46 |
Dagmar Hofmann, Eva Gans, Jasmin Krüll, Markus R. Heinrich. Sustainable Synthesis of Balsalazide and Sulfasalazine Based on Diazotization with Low Concentrations of Nitrogen Dioxide in Air. Chemistry – A European Journal 2017; 23(17): 4042 doi: 10.1002/chem.201605359
|
| 47 |
Mahmoud E. Awad, Elizabeth Escamilla-Roa, Ana Borrego-Sánchez, César Viseras, Alfonso Hernández-Laguna, C. Ignacio Sainz-Díaz. Adsorption of 5-aminosalicylic acid on kaolinite surfaces at a molecular level. Clay Minerals 2019; 54(1): 49 doi: 10.1180/clm.2019.13
|
| 48 |
Wolfgang Kruis, Mauro Bafutto. Colonic Diverticular Disease. 2022; : 235 doi: 10.1007/978-3-030-93761-4_19
|
| 49 |
Hiromu Morikubo, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Satoshi Kuronuma, Osamu Takeuchi, Tenyo Shiba, Hiroki Kiyohara, Mao Matsubayashi, Shintaro Sagami, Masaru Nakano, Osamu Ikezaki, Tadakazu Hisamatsu, Yoichi Tanaka, Toshifumi Hibi. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition. Journal of Gastroenterology and Hepatology 2021; 36(8): 2116 doi: 10.1111/jgh.15411
|
| 50 |
Glenn Lemmens, Arno Van Camp, Stephanie Kourula, Tim Vanuytsel, Patrick Augustijns. Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. Pharmaceutics 2021; 13(2): 161 doi: 10.3390/pharmaceutics13020161
|
| 51 |
Daniel M. O'Connell, Jonathan Moses. Invited commentary to immunotherapy withdrawal by step‐down to mesalamine in pediatrics patients with ulcerative colitis. JPGN Reports 2024; doi: 10.1002/jpr3.12047
|
| 52 |
Alex Yu, Jason R. Baker, Ann F. Fioritto, Ying Wang, Ruijuan Luo, Siwei Li, Bo Wen, Michael Bly, Yasuhiro Tsume, Mark J. Koenigsknecht, Xinyuan Zhang, Robert Lionberger, Gordon L. Amidon, William L. Hasler, Duxin Sun. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. Molecular Pharmaceutics 2017; 14(2): 345 doi: 10.1021/acs.molpharmaceut.6b00641
|
| 53 |
Hyo Yeop Song, Geom Seog Seo. 5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis. The Korean Journal of Gastroenterology 2022; 79(1): 31 doi: 10.4166/kjg.2021.152
|
| 54 |
Kristine Paridaens, John R Fullarton, Simon P L Travis. Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis. JGH Open 2023; 7(7): 516 doi: 10.1002/jgh3.12935
|
| 55 |
Tomoki HONJO, Keshi TOYOTA, Masahiro KANADA, Tatsuki ITOH. Vitamin C Enema Advances Induction of Remission in the Dextran Sodium Sulfate-Induced Colitis Model in Rats. Journal of Nutritional Science and Vitaminology 2021; 67(2): 91 doi: 10.3177/jnsv.67.91
|
| 56 |
Hossein Shahdadi Sardou, Abbas Akhgari, Amir Hooshang Mohammadpour, Ali Beheshti Namdar, Hossein Kamali, Amir Hossein Jafarian, Hadi Afrasiabi Garekani, Fatemeh Sadeghi. Optimization study of combined enteric and time-dependent polymethacrylates as a coating for colon targeted delivery of 5-ASA pellets in rats with ulcerative colitis. European Journal of Pharmaceutical Sciences 2022; 168: 106072 doi: 10.1016/j.ejps.2021.106072
|
| 57 |
Catherine O’Reilly, Susan Mills, Mary C. Rea, Aonghus Lavelle, Subrata Ghosh, Colin Hill, R. Paul Ross. Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches. Microbiome Research Reports 2023; 2(4) doi: 10.20517/mrr.2023.41
|
| 58 |
Agnieszka Kokoszko-Bilska, Slawomir Sobkiewicz, Jakub Fichna. Inflammatory bowel diseases and reproductive health. Pharmacological Reports 2016; 68(4): 859 doi: 10.1016/j.pharep.2016.03.009
|
| 59 |
Bernadette Mödl, Monira Awad, Daniela Zwolanek, Irene Scharf, Katharina Schwertner, Danijela Milovanovic, Doris Moser, Katy Schmidt, Petra Pjevac, Bela Hausmann, Dana Krauß, Thomas Mohr, Jasmin Svinka, Lukas Kenner, Emilio Casanova, Gerald Timelthaler, Maria Sibilia, Sigurd Krieger, Robert Eferl. Defects in microvillus crosslinking sensitize to colitis and inflammatory bowel disease. EMBO reports 2023; 24(10) doi: 10.15252/embr.202357084
|
| 60 |
Nicolás Ortiz-López, Catalina Fuenzalida, María Soledad Dufeu, Araceli Pinto-León, Alejandro Escobar, Jaime Poniachik, Juan Pablo Roblero, Lucía Valenzuela-Pérez, Caroll J. Beltrán. The immune response as a therapeutic target in non-alcoholic fatty liver disease. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.954869
|
| 61 |
Dayanand Swami, Shafina Siddiqui, Urwashi Kumar, Shine Devarajan, Jyotirmoi Aich. One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer. Bulletin of the National Research Centre 2022; 46(1) doi: 10.1186/s42269-022-00939-1
|
| 62 |
Masoumeh Faramarzian, Seifollah Bahramikia, Marzieh Dehghan Shasaltaneh. In vitro investigation of the effect of mesalazine on amyloid fibril formation of hen egg-white lysozyme and defibrillation lysozyme fibrils. European Journal of Pharmacology 2020; 874: 173011 doi: 10.1016/j.ejphar.2020.173011
|
| 63 |
Suzan S. Taha, Diyar S. Ali. Simple cloud point microextraction based on indophenol dye formation for mesalazine determination in pharmaceutical and biological samples. Microchemical Journal 2023; 191: 108862 doi: 10.1016/j.microc.2023.108862
|
| 64 |
Niels Vande Casteele, Abhijeet Jakate, Brian McNamee, William J. Sandborn. Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study. British Journal of Clinical Pharmacology 2021; 87(3): 1141 doi: 10.1111/bcp.14479
|